Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA3 | P07451 | 3/20 | 0.53 |
| ▸ | CA4 | P22748 | 3/20 | 0.53 |
| ▸ | CA6 | P23280 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.53 |
| ▸ | CA5A | P35218 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salclobuzic Acid SCHEMBL15484586 | 0.99 | FABP4 (0.56) | FABP4CDK1CA1CA2CA12 | |
| Salclobuzic Acid SCHEMBL28863372 | 0.99 | FABP4 (0.56) | FABP4CDK1CA1CA2CA12 | |
| Salclobuzic Acid SCHEMBL30966700 | 0.99 | FABP4 (0.56) | FABP4CDK1CA1CA2CA12 | |
| Salclobuzic Acid SCHEMBL1070672 | 0.97 | FABP4 (0.55) | FABP4CDK1CA1CA2CA12 | |
| SCHEMBL4390458 | 0.96 | CDK1 (0.56) | FABP4CDK1CA1CA2CA12 | |
| SCHEMBL4624092 | 0.94 | MAPK1 (0.55) | FABP4CDK1CA1CA2CA12 | |
| SCHEMBL5654581 | 0.94 | MAPK1 (0.55) | FABP4CDK1CA1CA2CA12 | |
| SCHEMBL13593295 | 0.94 | MAPK1 (0.55) | FABP4CDK1CA1CA2CA12 | |
| SCHEMBL26702537 | 0.89 | CDK1 (0.55) | FABP4CDK1CA1CA2CA12 | |
| SCHEMBL2330956 | 0.88 | CDK1 (0.74) | FABP4CDK1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4651897-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | Syntis Bio, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| CN-118873509-A | Oral pharmaceutical composition | 西藏海思科制药有限公司 | 2024-11-01 | — | — | CN | claimed |
| US-20240261411-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | SYNTIS BIO, INC. | 2024-08-08 | — | — | US | claimed |
| WO-2024155958-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | SYNTIS BIO, INC. (US) | 2024-07-25 | — | — | WO | claimed |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | claimed |
| EP-4299052-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND A PERMEATION ENHANCER | Adocia (FR) | 2024-01-03 | — | — | EP | claimed |
| EP-4259799-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | Civi Biopharma, Inc. (US) | 2023-10-18 | — | — | EP | claimed |
| CN-116897206-A | Oral delivery of PCSK 9-targeting antisense conjugates | 四纬生物制药股份有限公司 | 2023-10-17 | — | — | CN | claimed |
| WO-2006124047-A9 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT | EMISPHERE TECH INC (US) | 2007-06-21 | — | — | WO | claimed |
| CN-1964724-A | Solid dosage forms of wetted heparin | EMISPHERE TECH INC (US) | 2007-05-16 | — | — | CN | claimed |
| EP-1781257-A2 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT | Emisphere Technologies, Inc. (US) | 2007-05-09 | — | — | EP | claimed |
| US-7208178-B2 | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-04-24 | — | — | US | claimed |
| WO-2006124047-A2 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-11-23 | — | — | WO | claimed |
| EP-1469827-A4 | POLYMORPHS OF SODIUM 4- (4-CHLORO-2-HYDROXYBENZOYL)AMINO BUTANOATE | EMISPHERE TECH INC (US) | 2006-08-16 | — | — | EP | claimed |
| WO-2006072070-A2 | PHARMACEUTICAL FORMULATIONS OF GALLIUM SALTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-07-06 | — | — | WO | claimed |
| US-20050250852-A1 | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-11-10 | — | — | US | claimed |
| EP-1469827-A2 | POLYMORPHS OF SODIUM 4- (4-CHLORO-2-HYDROXYBENZOYL)AMINO BUTANOATE | Emisphere Technologies, Inc. (US) | 2004-10-27 | — | — | EP | claimed |
| WO-2003057650-A2 | POLYMORPHS OF SODIUM 4-[(4-CHLORO-2-HYDROXYBENZOYL)AMINO]BUTANOATE | EMISPHERE TECHNOLOGIES, INC. (US) | 2003-07-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261411-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | FABP2, SLC10A2, FABP6 | FABP4 524/4885CDK1 2604/4885CA1 1690/4885 |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | FABP4 889/4885CDK1 3743/4885CA1 1982/4885 |
| US-20050250852-A1 | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate | SLC5A1, SLC2A4, SLC2A3 | FABP4 15/4885CDK1 2844/4885CA1 4019/4885 |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | FABP4 1506/4885CDK1 2420/4885CA1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.